2016 US Venture Capital Investment into Life Sciences Companies: An Analysis by Evolution Bioscience

In order to elucidate the focus of Venture Capital funding in the Biotechnology sector this year, Evolution Analysts have assessed the deals carried out by the Top 25 US Venture

Share
Evolution Infographic: The Rise & Diversification of Biologics

For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that highlight the rise and

Share
Evolution Biopharma IPO Analysis featured on Forbes

Evolution’s 2015 Biopharmaceutical IPO Analysis was featured in a recent article on Forbes. Science & Business correspondent Arlene Weintraub’s article, titled “Will Wall Street Volatility Dampen The Sizzling Biotech IPO

Share
Evolution Infographic – An Analysis of 2015 Therapeutic IPOs

In the first half of 2015 fifty therapeutics companies finalised their IPOs, raising over $5.17 billion across multiple global exchanges. Evolution Global Talent Attraction analysed the therapeutic targets and IPO

Share
Record-setting IPO for cancer immunotherapy company NantKwest

NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer,

Share
Celgene & Juno Therapeutics announce landmark deal for CAR-T Cancer Therapies

Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will leverage T cell therapeutic

Share
Kite Pharma & bluebird bio Announce Strategic Collaboration to Treat HPV-Associated Cancers

With the Cancer Immunotherapy market forecast to increase to $9 billion by 2022, it’s no surprise that the burgeoning sector has attracted the attention of biotech and pharma investors across

Share